Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM listed Evgen Pharma Plc (“Evgen”), a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.
Evgen’s core technology is Sulforadex®, a means of synthesising and concurrently stabilising the naturally occurring compound sulforaphane, a compound with anti-cancer and neuroprotective characteristics. Evgen have recently completed the STEM Phase II trial of SFX-01 on breast cancer. The study successfully met both primary end points with SFX-01 proving to stabilise and shrink endocrine resistant metastatic breast cancer with a Clinical Benefit Rate of c. 24%.
For more information visit the Company’s website: www.evgen.com
For further information please contact:
About Walbrook PR: www.walbrookpr.com
Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.
Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.
Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.